Photodynamic therapy using methylene blue to treat cutaneous leishmaniasis

Photomedicine and Laser Surgery

Volumn 29, Issue 10, 2011, Pages 711-715

  Song, Dennis ^a   Lindoso, José Angelo Lauletta ^a,b   Oyafuso, Luiza Keiko ^b   Kanashiro, Edite Hatsumi Yamashiro ^a   Cardoso, João Luiz ^c   Uchoa, Adjaci F ^a   Tardivo, João Paulo ^a   Baptista, Mauricio S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SES SP   (Brazil)

^c Hospital Vital Brasil   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY COMPOUNDS; AROMATIC COMPOUNDS; LIGHT SOURCES; VIRUSES;

ANTI-MICROBIAL ACTIVITY; COLORIMETRIC ASSAYS; CUTANEOUS LEISHMANIASIS; IN-VIVO EXPERIMENTS; MECHANISM OF ACTION; MEDICAL CONDITIONS; NON-COHERENT LIGHT; PHOTODYNAMIC THERAPY (PDT);

PHOTODYNAMIC THERAPY;

ENZYME INHIBITOR; METHYLENE BLUE;

ARTICLE; CASE REPORT; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; MALE; METHODOLOGY; PHOTOCHEMOTHERAPY; SKIN LEISHMANIASIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INJECTIONS, INTRALESIONAL; LEISHMANIASIS, CUTANEOUS; MALE; METHYLENE BLUE; PHOTOCHEMOTHERAPY;

EID: 80053643359     PISSN: 15495418     EISSN: None     Source Type: Journal    
DOI: 10.1089/pho.2010.2915     Document Type: Article

References (32)

1. Murray, H.W., Berman, J.D., Davies, C.R., and Saravia, N.G. (2005). Advances in leishmaniasis. Lancet. 366, 1561-1577. (Pubitemid 41540115)
2. Reithinger, R., Dujardin, J.C., Louzir, H., Pirmez, C., Alexander, B., and Brooker, S. (2007). Cutaneous leishmaniasis. Lancet Infect. Dis. 7, 581-596. (Pubitemid 47277438)
3. Jones, T.C., Johnson,W.D., Jr., Barretto, A.C., et al. (1987). Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J. Infect. Dis. 156, 73-83. (Pubitemid 17089387)
4. Croft, S.L., and Coombs, G.H. (2003). Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19, 502-508. (Pubitemid 37329659)
5. Costa, J.M.L., Nascimento, S.A., Sampaio, D., et al. (2009). [Clinical aspects, diagnosis and therapeutic management of cutaneous leishmaniasis in Brazil]. G.M. Bahia 79 (Suppl. 3), 70-83.
6. Mahajan, V.K., Sharma, N.L. (2007). Options for cutaneous leishmaniasis. J. Dermatol. Treat. 18, 97-104.
7. Akilov, O.E., Kosaka, S., O'Riordan, K., et al. (2006). The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against Leishmania parasites. Chem. Biol. 13, 839-847. (Pubitemid 44247774)
8. Akilov, O.E., Kosaka, S., O'Riordan K., and Hasan T. (2007). Photodynamic therapy for cutaneous leishmaniasis: The effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation. Photochem. Photobiol. Sci. 6, 1067-1075. (Pubitemid 47525000)
9. Bristow, C.A., Harold, R., Paget, T.A., and Boyle, R.W. (2006). Potential of cationic porphyrins for photodynamic treatment of cutaneous leishmaniasis. Photodiagnosis Photodyn. Ther. 3, 162-167. (Pubitemid 44143044)
10. Akilov, O.E., Kosaka, S., O'Riordan, K., and Hasan, T. (2007). Parasiticidal effect of delta-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and mediated through the killing of the host cells. Exp. Dermatol. 16, 651-660. (Pubitemid 47079595)
11. Asilian, A., and Davami, M. (2006). Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: A placebo-controlled, randomized clinical trial. Clin. Exp. Dermatol. 31, 634-637. (Pubitemid 44086787)
12. Enk, C.D., Gardlo, K., Hochberg, M., Ingber, A., and Ruzicka T. (2003). [Cutaneous leishmaniasis]. Hautarzt 54, 506-512. (Pubitemid 36723197)
13. Gardlo, K., Horska, Z., Enk, C.D., et al. (2003). Treatment of cutaneous leishmaniasis by photodynamic therapy. J. Am. Acad. Dermatol. 48, 893-896. (Pubitemid 36706223)
14. Gardlo, K., Hanneken, S., Ruzicka, T., and Neumann, N.J. (2004). Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality. Hautarzt 55, 381-383. (Pubitemid 38661284)
15. Ghaffarifar, F., Jorjani, O., Mirshams, M., Miranbaygi, M.H., and Hosseini, Z.K. (2006). Photodynamic therapy as a new treatment of cutaneous leishmaniasis. East. Mediterr. Health J. 12, 902-908. (Pubitemid 46358288)
16. Sohl, S., Kauer, F., Paasch, U., and Simon, J.C. (2007). Photodynamic treatment of cutaneous leishmaniasis. J. Dtsch. Dermatol. Ges. 5, 128-130. (Pubitemid 46212729)
17. Modabber, F., Buffet, P.A., Torreele, E., Milon, G., and Croft S.L. (2007). Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Kinetoplastid. Biol. Dis. 6, 3-27.
18. Tardivo, J.P., Del Giglio, A., Oliveira, C.S., et al. (2005). Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications. Photodiagnosis Photodyn. Ther. 2, 175-191. (Pubitemid 41751085)
19. Gutmann, P., and Eherlich, P. (1981). First description of the use of a synthetic drug to treat disease, methylene blue as a treatment for malaria. Klin. Wochenschr. 39, 953-956.
20. Orth, K., Russ, D., Beck, G., Ruck A., and Berger, H.G. (1998). Photochemotherpy of experimental colonic tumors with intra-tumorally applied methylene blue. Photochem. Photobiol. 75, 392-397.
21. Tardivo, J.P., Del Giglio, A., Pashoal, L.H., Ito, A.S., and Baptista, M.S. (2004). Treatment of Melanoma Lesions Using Methylene Blue and RL50 Light Source. Photodiagnosis Photodyn. Ther. 1, 345-346. (Pubitemid 40460322)
22. Muller-Breitkreutz, K., and Mohr, H. (1998). Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J. Med. Virol. 56, 239-245. (Pubitemid 28458092)
23. Shih, M.H., and Huang, F.C. (2011). Effects of Photodynamic Therapy on Rapidly Growing Non-tuberculous Mycobacteria Keratitis. Invest. Ophthalmol. Vis. Sci. 52, 223-229.
24. Akilov, O.E., Kosaka, S., O'Riordan, K., and Hasan, T. (2007). Parasiticidal effect of d-aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis is indirect and medicated through the killing of the host cells. Exp. Dermatol. 16, 651-660. (Pubitemid 47079595)
25. Junqueira, H.C., Severino, D., Dias, L.G., Gugliotti, M., and Baptista, M.S. (2002). Modulation of the methylene blue photochemical properties based on the adsorption at aqueous micelle interfaces. Phys. Chem. Chem. Phys. 4, 2320-2328.
26. Kiderlen, A.F., and Kaye, P.M. (1990). A Modified colorimentri assay of macrophage activation for intracellular cytotoxicity against Leishmania parasites. J. Immunol. Methods 127, 11-18. (Pubitemid 20066271)
27. Moreira, M.E., Del, Portillo, H.A., Milder, R.V., Balanco, J.M., and Barcinski, M.A. (2004). Heat shock induction of apoptosis in promastigotes of the unicellular organism Leishmania (Leishmania) Amazonensis. J. Cell Physiol. 167, 305-313.
28. Tardivo, J.P., and Baptista, M.S. (2009). Treatment of osteomyelitis in the feet of diabetic patients by photodynamic antimicrobial chemotherapy. Photomed. Laser Surg. 27, 145-150.
29. Oliveira-Neto, M.P., Schubach, A., Mattos, M., Goncalves-Costa, S.C., and Pirmez, C. (1997). A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10 years). Am. J. Trop. Med. Hyg. 57, 651-655. (Pubitemid 28049378)
30. Oliveira-Neto, M.P., Schubach, A., Mattos, M., Goncalves-Costa, S.C., and Pirmez, C. (1997) Treatment of American cutaneous leishmaniasis: A comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol. Biol. (Paris) 45, 496-499. (Pubitemid 27306145)
31. Oliveira-Neto, M.P., and Mattos M. (2006). Successful therapeutic response of resistant cases of mucocutaneous leishmaniasis to a very low dose of antimony. Rev. Soc. Bras. Med. Trop. 39, 376-378. (Pubitemid 44476866)
32. Kosaka, S., Akilov, O.E., O'Riordan, K., and Hasan, T. (2007). A Mechanistic study of d-Aminolevulinic acid-based photodynamic therapy for cutaneous leishmaniasis. J. Invest. Dermatol. 127, 1546-1549. (Pubitemid 46762980)